Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands

OBJECTIVES: Multiple studies showed positive effects of Lutetium-Octreotate (LO) treatment in neuroendocrine tumours. LO has been used in the Netherlands since the 1980s and recently received the orphan status shortly after the acquisition by Novartis. Since then, the official list price has increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagendijk, Marije E., van der Schans, Simon, Boersma, Cornelis, Postma, Maarten J., van der Pol, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275500/
https://www.ncbi.nlm.nih.gov/pubmed/33829344
http://dx.doi.org/10.1007/s10198-021-01303-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275500/
https://www.ncbi.nlm.nih.gov/pubmed/33829344
http://dx.doi.org/10.1007/s10198-021-01303-2

Ejemplares similares